James H. Lewis

Gastroenterology
3800 Reservoir Rd NW Bldg 2 Rm 2210
Washington, DC 20007

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications

Tolebrutinib liver safety: A detailed overview.

Tolebrutinib liver safety: A detailed overview.

Journal: Multiple sclerosis and related disorders
Published: May 28, 2026

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant.

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant.

Journal: Drug safety
Published: April 17, 2026

Modifying Hy's Law and eDISH for the modern idiosyncratic DILI era.

Modifying Hy's Law and eDISH for the modern idiosyncratic DILI era.

Journal: Expert opinion on drug metabolism & toxicology
Published: October 25, 2025

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant.

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant.

Journal: Drug safety
Published: September 16, 2025

The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.

The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.

Journal: Drug safety
Published: July 13, 2025

Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Journal: Drug safety
Published: May 27, 2025

Managing Aminotransferase Elevations in Patients with Friedreich Ataxia Treated with Omaveloxolone: A Review and Expert Opinion on Use Considerations.

Managing Aminotransferase Elevations in Patients with Friedreich Ataxia Treated with Omaveloxolone: A Review and Expert Opinion on Use Considerations.

Journal: Neurology and therapy
Published: March 04, 2025

Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature.

Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature.

Journal: Drug safety
Published: January 16, 2025

Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis.

Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis.

Journal: Expert opinion on drug safety
Published: August 30, 2024

Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge.

Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge.

Journal: ACG case reports journal
Published: June 09, 2024

Traumatic Native Hip Dislocations: An Audit at a Major Trauma Centre and Assessment of Clinical Practice at Centres Across the United Kingdom.

Traumatic Native Hip Dislocations: An Audit at a Major Trauma Centre and Assessment of Clinical Practice at Centres Across the United Kingdom.

Journal: Cureus
Published: April 15, 2024

Mapping vulnerability to climate-related hazards to inform local authority action in adaptation: A feasibility study.

Mapping vulnerability to climate-related hazards to inform local authority action in adaptation: A feasibility study.

Journal: Public health in practice (Oxford, England)
Published: March 22, 2024
Showing 1-12 of 97

Last Updated: 09/26/2026